Realizing the Potential of RNA Therapeutics

miRecule™ is an early-stage biotechnology company developing RNA-based therapeutics. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient.

Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

miRecule is currently applying the DREAmiR platform to develop first-in-class therapies, with lead programs in Head & Neck Cancer and Muscular Dystrophy.

miRecule interviewed in the Washington Business Journal!

Anthony Saleh’s biotech, miRecule, is using microRNA therapeutics to treat cancers. This seed round will send the startup into the next phase of its journey toward clinical trials. – Washington Business Journal

miRecule published in Clinical Cancer Research!

Integrated genomic and functional microRNA analysis identifies miR-30-5p as a tumor suppressor and potential therapeutic nanomedicine in head and neck cancer – Clinical Cancer Research

miRecule featured by the BioHealth Capital Region Investment Conference!

miRecule closes Seed Round at the second annual BioHealth Capital Region Investment Conference  – BioBuzz

miRecule featured by the FSHD Society!

miRecule, Inc., is developing a novel treatment for FSHD – FSHD Society

miRecule awarded grant by Friends of FSH Research!

Antisense Oligonucleotide-Antibody Conjugates to Treat FSHD – Friends of FSH Research

miRecule adds Maryland Momentum Fund to its Seed Round!

USM Maryland Momentum Fund Invests $250,000 in $3.5M Seed Round of miRecule Inc. – USM Momentum Fund